Glucagon(19-29),human

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

64790-15-4

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
25mg	电议

产品介绍

化学性质

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	1352.51
Cas No.	64790-15-4
Formula	C₆₁H₈₉N₁₅O₁₈S
Synonyms	H2N-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH
Solubility	insoluble in EtOH; insoluble in H2O; ≥135.2 mg/mL in DMSO
Chemical Name	Glucagon (19-29), human
Canonical SMILES	CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)N
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Glucagon是由胰腺分泌的一种肽类激素，氨基酸序列为NH2-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-COOH，可增加体内血糖水平。胰高血糖素的作用与胰岛素相反，胰岛素可以降低血糖含量。促分泌素可诱导胰岛素释放，Miniglucagon（胰高血糖素19-29）通过钙离子途径高效的抑制这个过程。Miniglucagon是胰岛生理学的一种新型的局部调节剂。在2型糖尿病中观察到，这种肽在β细胞中诱导的异常抑制可导致胰岛素分泌受损。Miniglucagon是胰高血糖素正性肌力作用的一种成分。证据表明，胰高血糖素在心脏收缩过程中发挥正性肌力作用，胰高血糖素转变成miniglucagon的过程对于正向肌力作用的产生是必不可少的。

A1019_1
参考文献：

1. Reece J, Campbell N (2002). Biology. San Francisco: Benjamin Cummings. ISBN 0-8053-6624-5.

2. Stéphane Dalle, Ghislaine Fontés, Anne-Dominique Lajoix2, Laurence LeBrigand, René Gross, Gérard Ribes, Michel Dufour, Léo Barry, Dung LeNguyen and Dominique Bataille, Miniglucagon (Glucagon 19-29) A Novel Regulator of the Pancreatic Islet Physiology, doi:10.2337/diabetes.51.2.406Diabetes February 2002 vol. 51 no. 2406-412

3. Pavoine C, Brechler V, Kervan A, Blache Kervan, Le-Nguyen D, Laurent S, Bataille D, Pecker F (1991) Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am J Physiol 260:C993–C999.

试验操作

Cell experiment:[1]
Cell lines	MIN6 cells
Reaction Conditions	0.01 ~ 1000 pM miniglucagon for 2 h incubation
Applications	Miniglucagon dose-dependently (ID50 = 1 pM) inhibited by 80 ~ 100% the insulin release triggered by glucose, glucagon, glucagon-like peptide-1-(7-36) amide (tGLP-1), or glibenclamide. Miniglucagon, at the doses active on insulin release, was able to block the increase in⁴⁵Ca²⁺uptake induced by depolarizing agents (glucose or extracellular K⁺), glucagon, or the Ca²⁺channel agonist Bay K-8644. In addition, pretreatment with pertussis toxin abolished the effects of miniglucagon on insulin release. These data suggest that miniglucagon is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca²⁺channels linked to a pathway involving a pertussis toxin-sensitive G protein.
Note	The technical data provided above is for reference only.
	References: 1. Dalle S, Smith P, Blache P, et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca²⁺pathway. Journal of Biological Chemistry, 1999, 274(16): 10869-10876.